Table 2.
New diagnoses of other chronic comorbidities in the cohort during the six months before the lockdown, the first six months and from six to twelve months after the lockdown
| New diagnosis of chronic comorbidities (Yes %), N (%) | 6 months before lockdown (n = 662,754) | 0–6 months after lockdown (n = 654,954) | 6–12 months after lockdown (n = 649,702) | Cochran’s Q test, P |
|---|---|---|---|---|
| Arrhythmias | 2965 (0.4) | 1864 (0.3) | 667 (0.1) | < 0.001 |
| Heart failure | 1184 (0.2) | 924 (0.1) | 316 (0.03) | < 0.001 |
| Ischaemic heart disease | 1914 (0.3) | 1483 (0.2) | 530 (0.1) | < 0.001 |
| Hypertension | 3382 (0.5) | 2011 (0.3) | 956 (0.1) | < 0.001 |
| Dyslipidaemia | 4707 (0.7) | 2741 (0.4) | 1105 (0.2) | < 0.001 |
| Obesity | 1269 (0.2) | 512 (0.1) | 204 (0.05) | < 0.001 |
| Vein/artery disease | 683 (0.1) | 391 (0.05) | 167 (0.02) | < 0.001 |
| Cerebrovascular disease | 1588 (0.2) | 1349 (0.2) | 436 (0.06) | < 0.001 |
| Diabetes | 1709 (0.3) | 1181 (0.2) | 560 (0.1) | < 0.001 |
| Chronic bronchitis | 273 (0.04) | 132 (0.02) | 43 (0.006) | < 0.001 |
| COPD | 723 (0.1) | 230 (0.03) | 82 (0.01) | < 0.001 |
| Asthma | 653 (0.09) | 318 (0.04) | 71 (0.01) | < 0.001 |
| Chronic kidney disease | 2469 (0.4) | 2022 (0.3) | 646 (0.1) | < 0.001 |
| Smoking | 3208 (0.47) | 914 (0.13) | 285 (0.04) | < 0.001 |
| Alcoholism | 316 (0.04) | 238 (0.03) | 63 (0.009) | < 0.001 |
| Insomnia | 4539 (0.7) | 3427 (0.5) | 1107 (0.2) | < 0.001 |
| Anxiety and depression | 10,549 (1.6) | 9287 (1.4) | 1807 (0.3) | < 0.001 |
| Autolytic attempt | 170 (0.02) | 149 (0.02) | 72 (0.01) | < 0.001 |
| Anaemia | 4458 (0.7) | 3309 (0.5) | 1083 (0.2) | < 0.001 |
| Neoplasia | 9817 (1.46) | 6545 (1.0) | 2048 (0.3) | < 0.001 |
| Dementia | 1328 (0.2) | 1075 (0.2) | 356 (0.05) | < 0.001 |
| Hearing loss | 2238 (0.3) | 1177 (0.2) | 393 (0.05) | < 0.001 |
| Cataracts | 3691 (0.6) | 2360 (0.4) | 733 (0.1) | < 0.001 |
| Glaucoma | 1042 (0.15) | 496 (0.07) | 224 (0.03) | < 0.001 |
Bold values indicate that the results are statistically significant.